corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

All items in the Healthy Skepticism Library

All the 20545 items in the Healthy Skepticism Library are listed below in order of publication date with the most recent at the top. There are 100 items per page.

Page 201 of 206 pages ‹ First  < 199 200 201 202 203 >  Last ›

HSL2873
Hargraves R.
Introduction
Journal of Drug Issues 1976;6:1-5

HSL2878
Lexchin J.
About those drug ads . . .
Canadian Family Physician 1976;22:109-110

HSL2879
McCaffery M.
About those drug ads . . .
Canadian Family Physician 1976;22:110

HSL2880
Morgan AH, Jeffers TA, Petrie JC, Walker W.
Drug advertising in medical journals
British Journal of Clinical Pharmacology 1976;3:1057-1060

HSL2881
Mosher EH.
Portrayal of women in drug advertising: a medical betrayal
Journal of Drug Issues 1976;6:72-78

HSL2882
Nelson G.
Advertising and the national health
Journal of Drug Issues 1976;6:28-33

HSL2883
Petersen B, Kuriansky JB, Konheim CS, Anderson RS, Tesar J, Podell RN, Ho A, Cowan NM.
Television advertising and drug use
American Journal of Public Health 1976;66:(10):975-978

HSL2884
Schwartzman D.
Promotional expenditures
The Johns Hopkins University Press 1976;182-211

HSL2885
Silverman M, Lee PR.
Pills, profits & politics
University of California Press 1976;

HSL2886
Singer R.
Ads and readers
Canadian Family Physician 1976;22:635

HSL2887
Smith MC.
Portrayal of the elderly in prescription drug advertising
The Gerontologist 1976;16:329-334

HSL2888
Spiller GW.
Ads and readers
Canadian Family Physician 1976;22:635

HSL2889
Stimson GV.
The extent of advertising of pharmaceutical products.
J R Coll Gen Pract 1976;26:

HSL2890
Stimson GV.
The use of references in drug advertisements.
J R Coll Gen Pract 1976;26:

HSL2900
Brooke P.
Promotional parameters: a preliminary examination of promotional expenditures
Journal of Drug Issues 1976;6:(1):21-27

HSL2901
Choate R, Debevoise N.
Caution! Keep this commercial out of reach of children!
Journal of Drug Issues 1976;6:(1):91-98

HSL2902
Cope JD.
Television advertising of nonprescription medicines: The case for the defendant
Journal of Drug Issues 1976;6:(1):85-90

HSL2903
Donegan TJ.
The role of the Federal Trade Commission in regulating drug advertising: 1975 perspective
Journal of Drug Issues 1976;6:(1):99-104

HSL2904
Halberstam M.
The other side of the coin: another physician views drug advertising
Journal of Drug Issues 1976;6:(1):9-12

HSL2905
Jensen GF, Christiansen RL.
Drug advertising should be banned: Utah's approach
Journal of Drug Issues 1976;6:(1):65-71

HSL2906
Kuriansky JB.
TV advertising and abuse of over-the-counter drugs
Journal of Drug Issues 1976;6:(1):79-84

HSL2907
Nellis M.
Ineffectiveness x Delay = Danger: a public health equation for failure
Journal of Drug Issues 1976;6:(1):56-59

HSL2908
Pekkanen J.
The impact of promotion on physicians' prescribing patterns
Journal of Drug Issues 1976;6:(1):13-20

HSL2909
Reinstein P.
A regulator's perception of drug advertising
Journal of Drug Issues 1976;6:(1):60-64

HSL2910
Rucker TR.
Drug information for practitioners: commercial obligation or social responsibility?
Journal of Drug Issues 1976;6:(1):43-49

HSL2911
Ruskin A.
Social and regulatory consequences of misleading medical information
Journal of Drug Issues 1976;6:(1):50-55

HSL2912
Stetler CJ.
Advertising of prescription medicines.
Journal of Drug Issues 1976;6:(1):34-42

HSL2913
Watson M.
A physician views drug advertising
Journal of Drug Issues 1976;6:(1):

HSL8574
Stahel AI.
Time for decision
Australian Journal of Hospital Pharmacy 1976;6:(1):20-21

HSL9087
Silverman MM
The Drugging of the Americas: How Multinational Drug Companies Say One Thing About Their Products to Physicians in the United States and Another Thing to Physicians in Latin America
Berkeley: University Of California Press 1976
http://www.amazon.com/Drugging-Americas-Multinational-Companies-Physicians/dp/0520031229/ref=sr_1_1/102-1249992-1219339?ie=UTF8&s=books&qid=1175307707&sr=1-1

HSL8843
Mixson P.
Britain's nationalized pharmacy: lesson for the U.S.
Drug Topics 1975 Dec 1;119:21, 26-27

HSL8571
What you should know about the FTC
J Am Pharm Assoc. 1975 Dec;15:(12):668-77

HSL8842
Smiler BA.
Drugs in dentistry
Medical Marketing and Media 1975 Dec;10:13-16

HSL2857
Stimson GV.
Information contained in drug advertisements.
BMJ. 1975 Nov 29;4:(5995):508-9

HSL2856
Jacoby J, Small C.
The FDA approach to defining misleading advertising
Journal of Marketing 1975 Oct;39:65-73

HSL8573
Whitney HA Jr.
Educating the public about drugs.
Drug Intell Clin Pharm 1975 Oct;9:(10):571

HSL8846
Kleinfeld VA.
Overview of some recent developments in the drug field
Food Drug Cosmet Law J 1975 Aug;30:458-468

HSL8844
Stetler CJ.
Are drug prices an profits without honor?
Medical Marketing and Media 1975 Jul;10:11-12, 14, 16

HSL8849
Kushner D.
FTC's rules: get set for long controversy
American Druggist 1975 Jul;172:18, 37-44, 47

HSL8847
Mant A.
Determinants of prescribing of psychoactive drugs by general practitioners.
Med J Aust 1975 Jun 14;1:(24):743-9

HSL2062
Stimson GV.
The message of psychotropic drug ads.
J Commun 1975 Summer;25:(3):153-60

HSL2843
Harelik JH, Johnston PM, Rivers NP, Ryan MR.
Pharmacist and physician evaluation of drug information sources.
Am J Hosp Pharm 1975 Jun;32:(6):594-7

HSL2842
Bell W
The Compendium of Pharmaceuticals and Specialties
1975 May 30-31;

HSL2846
Mailloud J.
The drug companies role in the supply of information
1975 May 30-31;

HSL2855
Stimson G.
Women in a doctored world
New Society 1975 May 1;32:265-267

HSL2852
Williamson PM.
How general practitioners assess risks in using new drugs.
J R Coll Gen Pract 1975 May;25:(154):383-6

HSL8845
Ellenhorn MJ.
Future shock: drug therapy and the US pharmaceutical industry
Journal of Clinical Pharmacology 1975 May-Jun;15:385-400
http://jcp.sagepub.com/cgi/reprint/15/5/385

HSL8851
Barrows J.
Prescription drug labeling for patients
Food Drug Cosmet Law J 1975 Feb;30:98-104

HSL8855
Hemminki E.
Review of literature on the factors affecting drug prescribing.
Soc Sci Med 1975 Feb;9:(2):111-6

HSL2849
Prather J, Fidell LS.
Sex differences in the content and style of medical advertisements.
Soc Sci Med 1975 Jan;9:(1):23-6

HSL2850
Smith GH, Sorby DL, Sharp LJ.
Physician attitudes toward drug information resources.
Am J Hosp Pharm 1975 Jan;32:(1):19-25

HSL8839
Higgins DG.
Aspects of medical communications in the United Kingdom.
Drug Inf J 1975 Jan-Apr;9:(1):32-7

HSL2841
Prescription drug ads now to be prescreened
Canadian Family Physician 1975;21:(8):23

HSL2844
Huse KD.
Medical advertising—the other side of the coin
Patient Management 1975;4:(6):36-37

HSL2845
Kales A, Kales JD.
Shortcomings in the evaluation and promotion of hypnotic drugs
New England Journal of Medicine 1975;293:826-827

HSL2847
Mant A, Darroch DB.
Media images and medical images
Social Science and Medicine 1975;9:613-618

HSL2848
McCaffery M.
The muzzle muddle
Canadian Family Physician 1975;21:(11):7

HSL2851
Telser L, Best W, Egan JW, Higinbotham HN.
The theory of supply with applications to the ethical pharmaceutical industry
Journal of Law and Economics 1975;18:449-478

HSL2853
Responsible advertising
Medical Journal of Australia 1975;62:90

HSL2854
Erill S, Souich PD, Garcia-Sevilla JA.
Chloramphenicol-containing drugs. A report from Spain
J Clin Pharmacol . 1975;15:401-404
http://jcp.sagepub.com/cgi/reprint/15/5/401

HSL8576
Rucker TD.
Role of the pharmaceutical industry in a dynamic health care system
Drugs Health Care 1975;2:(2):86-95

HSL8577
Lee AM.
Interdependence of prescription drugs and other health care costs
Drugs Healt -Care 1975;2:(2):75-85

HSL8578
Hornbrook MC.
Commentary on the interdependence of prescription drugs and other health care costs: some implications for research
Drugs Health Care 1975;2:(4):255-265

HSL8850
Pharmacy board not authorized to prohibit drug price advertising
Citation 1975;30:(6):

HSL8856
Manufacturer liable for erroneous drug addiction claims
Citation 1975;30:(7):107-108

HSL9052
Illich I.
Medical Nemesis
: Calder & Boyar 1975
http://www.amazon.com/Medical-Nemesis-Ivan-Illich/dp/0394712455

HSL9059
Klass A.
There's Gold in Them Thar Pills: An Enquiry into the Medical-Industrial Complex
: Penguin 1975
http://www.amazon.com/Theres-Gold-Them-Pills-Medical-Industrial/dp/0140523146/ref=sr_1_1/102-1249992-1219339?ie=UTF8&s=books&qid=1175165931&sr=1-1

HSL12234
Levine JM, Valle RS.
The convert as a credible communicator
Social Behavior and Personality 1975;3:81-90

HSL2825
Woods D.
Prescription drugs and the patient's health.
Can Med Assoc J 1974 Dec 7;111:(11):1269

HSL8858
Steiner KC, Garner DD.
Price as a component of prescription drug advertising
Medical Marketing and Media 1974 Dec;9:15-20

HSL2840
Dryden A.
PMAC setting up board to pre-clear ads
Maclean Hunter 1974 Nov 18;79:3

HSL2817
Mcree C, Corder BF, Haizlip T.
Psychiatrists' responses to sexual bias in pharmaceutical advertising.
Am J Psychiatry 1974 Nov;131:(11):1273-5

HSL8569
Response of the American Pharmaceutical Association to the June 14, 1974, inquiry of the Federal Trade Commission.
J Am Pharm Assoc 1974 Oct;14:(10):538-42,

HSL2819
Moser RH.
Editorial: The continuing search: FDA drug information survey.
JAMA 1974 Sep 2;229:(10):1336-8

HSL2810
Erill S.
Clinical pharmacology in Spain.
Clin Pharmacol Ther 1974 Sep;16:(3):597-604

HSL2839
Editorial
Advertising standards and the National Medical Media Council.
Med J Aust. 1974 Aug 10;2:(6):189-90

HSL2838
Siegelman S.
How pharmacists rate detailmen
American Druggist 1974 Aug 1;170:(3):19, 56-62

HSL2821
Schreier HA, Berger L.
Letter: On medical imperialism.
Lancet 1974 Jun 8;1:(7867):1161

HSL8862
Walters PG.
FDA's program to improve consumers' and health professionals' ability to select medically effective drugs
Hosp Formul Manage 1974 Jun;9:17-20, 50

HSL2826
Gould D.
Can we handle modern drugs?
New Scientist 1974 May 23;62:(899):460-1

HSL2827
Greenberg D.
Cleaning up the drug trade
New Scientist 1974 May 23;62:491

HSL8869
Inquisitive Federal Trade Commission (FTC) starts poking into pharmacy field
American Druggist 1974 May 1;169:74-75

HSL8854
Schamberg IL.
The quality and cost of prescription drugs.
J Am Pharm Assoc 1974 May;14:(5):241-3

HSL8861
Pendergast WR.
FDA regulations-a ten-year assessment
Medical Marketing and Media 1974 May;9:20, 22, 26-27

HSL2813
Hemminki E.
The effect of a doctor's personal characteristics and working circumstances on the prescribing of psychotropic drugs.
Med Care 1974 Apr;12:(4):351-7

HSL8870
Decristoforo R, Fortner CL.
Review of potential drug interactions between OTC (over-the-counter) and prescription drugs
Hosp Formul Manage 1974 Apr;10:20-31, 41

HSL8866
Davis S.
Update on computerized media evaluation
Medical Marketing and Media 1974 Mar;9:13-15

HSL8874
Display the prescription price poster, but not too conspicuously
Am Drug Merch 1974 Feb 1;169:32-36, 46

HSL8859
Miller R.
Prescribing habits of physicians. Parts 7-8. Sources of information on drugs and their influence on prescribing and a theoretical model for the adoption of drug innovations
Drug Intell Clin Pharm 1974 Feb;8:81-91

HSL8863
Hoare RG.
Pharmaceutical company
Postgrad Med J 1974 Feb;50:85-87

HSL2806
Denies ads mislead, manipulate
Drug Merchandising 1974;55:(4):51

HSL2807
Findings and conclusions of the NCCC [National Council of Churches of Christ] project on drug advertising
Journal of Drug Issues 1974;4:310-312

HSL2808
Bowes R.
The industry as pusher
Journal of Drug Issues 1974;4:238-242

HSL2809
Cooperstock R.
Some factors involved in the increased prescribing of psychotropic drugs
Alcoholism and Drug Addiction Research Foundation of Ontario 1974;

HSL2811
Greenfield P, Wolff F.
The pressures of drug advertising on physicians and patients
Journal of Drug Issues 1974;4:254-259

HSL2812
Hay DR.
Postal pollution
New Zealand Medical Journal 1974;80:464

HSL2814
Hess SW.
Communicating with physicians
Journal of Advertising Research 1974;14:(1):13-18

HSL2815
Kallir J.
An advertiser’s view of drug advertising
Journal of Drug Issues 1974;4:283-286

HSL2816
Knight JL, Baumgartner RP.
Quality control information—its availability from pharmaceutical manufacturers
Hospital Formulary Management 1974;9:(9):35, 37, 40-42, 50

HSL2818
Miller RR.
Prescribing habits of physicians: a review of studies on prescribing of drugs. Parts VII-Viii
Drug Intelligence and Clinical Pharmacy 1974;8:81-91

Page 201 of 206 pages ‹ First  < 199 200 201 202 203 >  Last ›

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.







...to influence multinational corporations effectively, the efforts of governments will have to be complemented by others, notably the many voluntary organisations that have shown they can effectively represent society’s public-health interests…
A small group known as Healthy Skepticism; formerly the Medical Lobby for Appropriate Marketing) has consistently and insistently drawn the attention of producers to promotional malpractice, calling for (and often securing) correction. These organisations [Healthy Skepticism, Médecins Sans Frontières and Health Action International] are small, but they are capable; they bear malice towards no one, and they are inscrutably honest. If industry is indeed persuaded to face up to its social responsibilities in the coming years it may well be because of these associations and others like them.
- Dukes MN. Accountability of the pharmaceutical industry. Lancet. 2002 Nov 23; 360(9346)1682-4.